SCHEMBL6894574

SCHEMBL6894574

CC(=O)OCC(=O)c1nc(C)n2ccsc12

nearest known ligand 0.40

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.40
ALDH1A1 P00352 4/20 0.38
KDM4E B2RXH2 4/20 0.38
HPGD P15428 4/20 0.38
HSD17B10 Q99714 3/20 0.38
TP53 P04637 3/20 0.38
RECQL P46063 1/20 0.35
MAPT P10636 2/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
LMNA P02545 2/20 0.32
SMN1; SMN2 Q16637 2/20 0.32
CYP1A2 P05177 1/20 0.32
TDP1 Q9NUW8 1/20 0.32
ALOX12 P18054 1/20 0.31
RXFP1 Q9HBX9 1/20 0.31
POLB P06746 1/20 0.31
HTR1A P08908 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6890889 0.81 MAPK1 (0.38) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6892437 0.81 MAPK1 (0.35) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6886875 0.74 ALDH1A1 (0.35) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL7638619 0.65 ALOX12 (0.44) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL6891044 0.62 CYP1A2 (0.36) MAPK1ALDH1A1KDM4EMAPTLMNA
SCHEMBL10994393 0.60 NPC1 (0.67) ALDH1A1HPGDTP53MAPTNPC1
SCHEMBL19700128 0.59 MAPK1 (0.63) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL2040055 0.59 MAPK1 (0.63) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL8054483 0.59 HPGD (0.40) MAPK1ALDH1A1KDM4EHPGDHSD17B10
SCHEMBL19148221 0.59 MAPK1 (0.63) MAPK1ALDH1A1KDM4EHPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6677331-B2 HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS MEIJI SEIKA KAISHA, LTD. (JP) 2004-01-13 US disclosed
US-20030149016-A1 Novel carbapenem derivatives KANO YUKO (JP) 2003-08-07 US disclosed
US-6458780-B1 IMIDAZO(5,1-B)THIAZOLE GROUP AT THE 2-POSITION ON THE CARBAPENEM RING HAVE HIGH ANTI-MICROBIAL ACTIVITIES AGAINST .BETA.-LACTAMASE PRODUCING BACTERIA, MRSA, RESISTANT-PSEUDOMONAS AERUGINOSA, PRSP, ENTEROCOCCI, AND MEIJI SEIKA KAISHA, LTD. (JP) 2002-10-01 US disclosed
EP-1101766-A1 NOVEL CARBAPENEM DERIVATIVES MEIJI SEIKA KAISHA LTD. (JP) 2001-05-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030149016-A1 Novel carbapenem derivatives DPEP1, TMPRSS15, STK35 MAPK1 1333/4885ALDH1A1 1161/4885KDM4E 1406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.